PortfoliosLab logoPortfoliosLab logo
GERM vs. IBB
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

GERM vs. IBB - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amplify Treatments, Testing and Advancements ETF (GERM) and iShares Nasdaq Biotechnology ETF (IBB). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


GERM

1D
0.00%
1M
0.00%
YTD
0.00%
6M
0.00%
1Y
0.00%
3Y*
5Y*
10Y*

IBB

1D
1.97%
1M
-1.56%
YTD
-0.68%
6M
-2.57%
1Y
34.50%
3Y*
9.40%
5Y*
2.10%
10Y*
6.23%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GERM vs. IBB - Yearly Performance Comparison


2026 (YTD)20252024
GERM
Amplify Treatments, Testing and Advancements ETF
0.00%0.00%0.00%
IBB
iShares Nasdaq Biotechnology ETF
-0.68%27.98%-7.21%

GERM vs. IBB - Sectors Allocation Comparison


Sectors
GERM
IBB

Healthcare

99.3%
100.0%

Financial Services

0.4%

-

Basic Materials

-

-

Communication Services

-

-

Consumer Cyclical

-

-

Consumer Defensive

-

-

Energy

-

-

Industrials

-

-

Real Estate

-

-

Technology

-

-

Utilities

-

-

Healthcare

GERM
99.3%
IBB
100.0%

Financial Services

GERM
0.4%
IBB

-

Basic Materials

GERM

-

IBB

-

Communication Services

GERM

-

IBB

-

Consumer Cyclical

GERM

-

IBB

-

Consumer Defensive

GERM

-

IBB

-

Energy

GERM

-

IBB

-

Industrials

GERM

-

IBB

-

Real Estate

GERM

-

IBB

-

Technology

GERM

-

IBB

-

Utilities

GERM

-

IBB

-

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GERM vs. IBB — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GERM

IBB
IBB Risk / Return Rank: 5656
Overall Rank
IBB Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
IBB Sortino Ratio Rank: 5050
Sortino Ratio Rank
IBB Omega Ratio Rank: 4646
Omega Ratio Rank
IBB Calmar Ratio Rank: 7171
Calmar Ratio Rank
IBB Martin Ratio Rank: 6262
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GERM vs. IBB - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amplify Treatments, Testing and Advancements ETF (GERM) and iShares Nasdaq Biotechnology ETF (IBB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

GERM vs. IBB - Sharpe Ratio Comparison


Loading charts...

Sharpe Ratios by Period


GERMIBBDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.74

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.10

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.27

Sharpe Ratio (All Time)

Calculated using the full available price history

0.26

Drawdowns

GERM vs. IBB - Drawdown Comparison

The maximum GERM drawdown since its inception was 0.00%, smaller than the maximum IBB drawdown of -62.85%. Use the drawdown chart below to compare losses from any high point for GERM and IBB.


Loading charts...

Drawdown Indicators


GERMIBBDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-62.85%

+62.85%

Max Drawdown (1Y)

Largest decline over 1 year

0.00%

-9.63%

+9.63%

Max Drawdown (3Y)

Largest decline over 3 years

-24.85%

Max Drawdown (5Y)

Largest decline over 5 years

-39.82%

Max Drawdown (10Y)

Largest decline over 10 years

-39.82%

Current Drawdown

Current decline from peak

0.00%

-5.64%

+5.64%

Average Drawdown

Average peak-to-trough decline

0.00%

-21.18%

+21.18%

Ulcer Index

Depth and duration of drawdowns from previous peaks

0.00%

3.03%

-3.03%

Volatility

GERM vs. IBB - Volatility Comparison

The current volatility for Amplify Treatments, Testing and Advancements ETF (GERM) is 0.00%, while iShares Nasdaq Biotechnology ETF (IBB) has a volatility of 6.86%. This indicates that GERM experiences smaller price fluctuations and is considered to be less risky than IBB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GERMIBBDifference

Volatility (1M)

Calculated over the trailing 1-month period

0.00%

6.86%

-6.86%

Volatility (6M)

Calculated over the trailing 6-month period

0.00%

15.38%

-15.38%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

19.89%

-19.89%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

21.99%

-21.99%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

23.22%

-23.22%

GERM vs. IBB - Expense Ratio Comparison

GERM has a 0.68% expense ratio, which is higher than IBB's 0.47% expense ratio.


Dividends

GERM vs. IBB - Dividend Comparison

GERM has not paid dividends to shareholders, while IBB's dividend yield for the trailing twelve months is around 0.23%.


PositionTTM20252024202320222021202020192018201720162015
GERM
Amplify Treatments, Testing and Advancements ETF
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
IBB
iShares Nasdaq Biotechnology ETF
0.23%0.23%0.29%0.26%0.31%0.21%0.21%0.33%0.20%0.30%0.19%0.03%

Frequently Asked Questions


IBB has higher volatility (6.86%) compared to GERM (0.00%). In terms of maximum drawdown, GERM dropped 0.00% vs IBB's -62.85%.

On 1-year performance, IBB leads with 34.50% vs 0.00% for GERM. On fees, IBB is cheaper at 0.47% per year. On volatility, GERM has been the lower-risk option at 0.00%. The better choice depends on whether you care most about return, fees, risk, or income.

Over the 1-year period, IBB has performed better with a 34.50% return vs 0.00%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

IBB is cheaper with a 0.47% expense ratio, compared with 0.68% for GERM.

IBB has the higher dividend yield at 0.23%, compared with 0.00% for GERM.

GERM tracks Prime Treatments, Testing and Advancements Index, while IBB tracks NASDAQ Biotechnology Index. They also come from different issuers: Amplify and iShares. Their fees differ too: 0.68% for GERM and 0.47% for IBB.

Portfolio Optimizer

Find the right allocation for GERM and IBB

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer